HYHalis Yerlikaya

Halis Yerlikaya

*This is an algorithmically generated author record based on publicly available information.

Halis Yerlikaya has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prognostıc Factors In Testıcular Cancer

    by Yasin Sezgin, Oğur Karhan, Abdurrahman Biçer, Serdy İleri, Halis Yerlikaya, Sezai Tunç, İbrahim Aydın, Muslih Ürün, Mehmet Naci Aldemir

    Aim: Testicular cancer is the most common cancer in men aged 15-35 years and accounts for 1% of all lifetime male cancers. There are two histologic subtypes: seminoma and nonseminoma. In our study, we aimed to investigate the factors predicting recurrence in early-stage testicular cancer. Materials and Methods: Our study is a retrospective study of early stage testicular cancer admitted to the medical oncololi clinic of our hospital between 2006-2018. During the study, 344 patient files were reviewed and 130 patients who met the study criteria were included in the study. Our primary aim in this study was to investigate the factors predictive of recurrence in early stage testicular cancer. Results: When evaluating PFS in patients with nonseminoma with and without lymphovascular invasion, no median PFS value was reached in either group. However, PFS was worse in patients with LVI (p=0.037). When comparing stage 1 with stage 2 seminoma patients, no median PFS values could be reached, but there was a statistical difference between the two groups in terms of recurrence (p=0.019). Conclusions: In our study, we found no association between tumor size, embryonal carcinoma predominance, tunica albuginea invasion, spermatic cord involvement and tumor marker values and recurrence in nonseminoma germ cell testicular tumors. PFS was shorter in patients with LVI compared to those without LVI. Lymphovascular invasion, spermatic cord involvement, tunica albuginea involvement, and rete testis involvement were not associated with disease recurrence in seminoma patients, whereas higher disease stage predicted the risk of recurrence.

  • Are Syrian refugee breast cancer patients diagnosed at advanced stage and do they have treatment delays?

    by Ogur Karhan, Şaban Secmeler, Yasin Sezgin, Serdar Ileri, Halis Yerlikaya

    Aim: To compare the clinicopathological features and time to reach treatment of patients with breast cancer among Syrian refugees (SRs) and Turkish citizens (TCs). Methods: Retrospective data from ... Tweetable abstract Patients with breast cancer among Syrian refugees are younger but are not diagnosed and treated later than Turkish citizens. #Syrian #refugees #TreatmentDelay #BreastCancer


  • Open Access

    REAL-LIFE DATA OF PAZOPANIB USAGE IN SOFT TISSUE SARCOMA

    by Oğur Karhan, Serdar İleri̇, Halis Yerli̇kaya, Muslih Ürün, Yasin Sezgi̇n

    Objective: Soft tissue sarcomas are heterogeneous group of malignancies consisting of more than 50 subtypes. Although it is rare, it is usually resistant to chemotherapy and has a poor prognosis. In this study, we planned to investigate the efficacy, tolerability and side-effect profile of pazopanib in metastatic soft tissue sarcomas. Method-Material: Our study was a single-center retrospective study and included metastatic patients over the age of 18 who were treated with pazopanib. Data of 37 patients were obtained in retrospective medical records. In patients using pazopanib; Tumor location, histological subtype, tumor grade, disease stage, the line at which pazopanib was used, efficacy, tolerability, and side-effect profile of pazopanib were examined. Findings: The mean age of the patients at diagnosis was 49. Pleomorphic sarcoma was the most common subtype. The progression-free survival (PFS) of patients after first-line therapy was 18 weeks. The median overall survival (OS) of the patients was 20 months. The median PFS with pazopanip was 18 weeks. Conclusion: In the study we conducted research in terms of effectiveness and side effects; the use of pazopanib in soft tissue sarcoma was found to be effective in terms of both PFS and OS. Side effects were tolerable and treatable. In our study, a PFS of 32 weeks was obtained in patients with hypothyroidism and at 16 weeks in patients who did not. In this respect, development of hypothyroidism may be a predictive parameter for response.


  • Factors Influencing HER2 Discordance in Nonmetastatic Breast Cancer and The Role of Neoadjuvant Therapy

    by Senar Ebinç, Zeynep Oruç, Yasin Sezgin, Oğur Karhan, Erkan Bilen, Halis Yerlikaya, Ziya Kalkan, Zuhat Urakçı, Mehmet Küçüköner, Muhammet Ali Kaplan, et al.

    Objective: The rates of and the factors influencing HER2 discordance in patients receiving neoadjuvant therapy for breast cancer are investigated. Methods: This study retrospectively examines the r... Plain language summary HER2 is an important and targetable molecule in breast cancer. In the early stages of breast cancer, a treatment modality called neoadjuvant therapy, which now includes anti-...


  • Open Access

    A metastatic malign melanoma case with diffuse cutaneous melanosis

    by Zeynep Oruç, Muhammet Ali Kaplan, Halis Yerlikaya, Zuhat Urakçı, Mehmet Küçüköner, Abdurrahman Işıkdoğan

    Diffuse Cutaneous Melanosis is a rare clinical condition characterized by rapidly acquired skin pigmentation that can occur in the course of advanced metastatic melanoma. A 59 year old patient with malign melanoma who developed diffuse cutaneous melanosis in the course of the disease is presented. He had multiple hepatic metastasis, lung metastasis, and multiple bone metastases. After the initiation of chemotherapy, he developed progressively darkening of the entire skin, darkened urine. Four months after the onset of melanosis, the patient died. The prognosis are poor in patients with diffuse cutaneous melanosis associated with malign melanoma